肺栓塞-晕厥、贫血和肾功能不全出血评分对急性肺栓塞患者早期大出血的外部验证:来自COMMAND VTE Registry-2
基于日本31中心COMMAND VTE Registry-2中2781例急性肺栓塞患者,按PE-SARD评分分为高危(>2.5分,557例)、中危(1-2.5分,1412例)和低危(0分,812例),评估30天大出血的区分度与校准度。30天累积大出血发生率随风险类别升高而增加(高危8.2%、中危4.6%、低危1.8%),C统计量0.65,评分<4分时校准良好(活动性癌症患者除外)。
要点
- PE-SARD评分高危(>2.5分)患者30天累积大出血发生率为8.2%(95%CI 5.9%-10.5%)。
- 评分区分度中等,C统计量0.65(95%CI 0.61-0.70)。
- 评分<4分时校准良好,但活动性癌症患者除外。
核心结论
- PE-SARD出血评分在无活动性癌症的急性肺栓塞患者中区分度中等,校准度有限。
研究设计与样本
- 基于COMMAND VTE Registry-2数据库,纳入2015年1月至2020年8月日本31个中心连续登记的5197例急性症状性静脉血栓栓塞症患者,识别出急性肺栓塞患者。
- 共2781例符合条件患者,按PE-SARD评分分为高危(>2.5分,557例,20%)、中危(1-2.5分,1412例,51%)和低危(0分,812例,29%)三组。
- 评估评分对30天大出血的区分度和校准度,并根据活动性癌症进行亚组分析。
主要发现
- 30天内121例患者发生大出血。
- 30天累积大出血发生率:高危组8.2%(95%CI 5.9%-10.5%),中危组4.6%(95%CI 3.5%-5.7%),低危组1.8%(95%CI 0.8%-2.7%),随风险类别升高而增加。
- 区分度中等,C统计量0.65(95%CI 0.61-0.70)。
- 评分<4分时校准良好,但活动性癌症患者除外。
关键数值与推荐
- PE-SARD评分分组:高危>2.5分,中危1-2.5分,低危0分。
- 30天累积大出血发生率:高危组8.2%(95%CI 5.9%-10.5%),中危组4.6%(95%CI 3.5%-5.7%),低危组1.8%(95%CI 0.8%-2.7%)。
- C统计量0.65(95%CI 0.61-0.70)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no established risk score for anticoagulant-related bleeding during the acute phase in patients with pulmonary embolism (PE). The PE-Syncope, Anemia, and Renal Dysfunction (PE-SARD) bleeding score was developed to predict early major bleeding but has not yet been fully externally validated. OBJECTIVES: To externally validate the PE-SARD bleeding score. METHODS: Using the COntemporary ManageMent AND outcomes in patients with Venous ThromboEmbolism (COMMAND VTE) Registry-2 database, which enrolled 5197 consecutive acute symptomatic venous thromboembolism patients among 31 centers in Japan between January 2015 and August 2020, we identified acute PE patients. We divided them into 3 groups by the score: high-risk (>2.5 points), intermediate-risk (1-2.5 points), and low-risk (0 points). The discriminating and calibration performances of the score for 30-day major bleeding were assessed. Subgroup analyses based on active cancer were also performed. RESULTS: Of 2781 eligible patients, the high-risk group accounted for 557 patients (20%), intermediate-risk group for 1412 (51%), and low-risk group for 812 (29%). Major bleeding occurred in 121 patients within 30 days. The cumulative 30-day incidence of major bleeding substantially increased in the higher risk categories by the score (high-risk group, 8.2% [95% CI, 5.9%-10.5%]; intermediate-risk group, 4.6% [95% CI, 3.5%-5.7%]; and low-risk group, 1.8% [95% CI, 0.8%-2.7%]). The discriminating power of the score was modest with a C statistic of 0.65 (95% CI, 0.61-0.70), with a good calibration performance with a score of <4 points, except for that in active cancer patients. CONCLUSION: The PE-SARD bleeding score had a modest discriminating performance with a limited calibration performance in acute PE patients without active cancer.
引用
- Nishimoto Y, Yamashita Y, Morimoto T, et al. External validation of the Pulmonary Embolism-Syncope, Anemia, and Renal Dysfunction bleeding score for early major bleeding in patients with acute pulmonary embolism: from the COMMAND VTE Registry-2. J Thromb Haemost. 2024. PMID: 38944241. doi:10.1016/j.jtha.2024.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。